Samsung Biologics has agreed to establish a US$300 M joint venture with Biogen Idec to develop, manufacture and market biosimilars. Samsung will have a majority 85% stake in the joint venture with a US$255 M investment, while Biogen Idec will contribute US$45 M for a 15% stake as well as its expertise in protein engineering and biologics manufacturing. The joint venture will not pursue the development of biosimilars of proprietary Biogen Idec products.